No Prescription |
 |
 | ||
|
Accu Chek Softclix |
|
| ||
No Prescription » Prescription Drugs 1 » Accu Chek Softclix The Accu-Chek Softclix. - So gentle it's virtually painless.And so easy you can use it with just one hand. Virtually Pain Free. The Accu-Chek Softclix uses an extremely precise motion and a fine non-stick silicon coated lancet so you have less tearing of skin or tissue. And that means less pain. With 11 different depth settings on the comfort dial you can choose the most comfortable lancing setting to suit your type of skin.Discrete Style. The Accu-Chek Softclix is a state-of-the-art medical device. The pen-like style makes it discreet and easy to handle. It even has a handy clip for when you're on the move. Buy Accu Chek Softclix and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Accu Chek Softclix: Product Type: Prescription Drugs 1 Accu-Chek Softclix Accu-Chek Softclix Accu-Chek Softclix Lancing 25 LNCTS Lancing Accu-Chek Softclix Accu-Chek Softclix
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
